<DOC>
	<DOCNO>NCT02054104</DOCNO>
	<brief_summary>Background : During recent year , cancer-testis ( CT ) antigens ( CTA ) , particularly encode gene X chromosome ( CT-X gene ) , emerge attractive target cancer immunotherapy . Whereas malignancies diverse histology express variety CTAs , immune response protein appear uncommon cancer patient , possibly due low-level , heterogeneous antigen expression , well immunosuppressive regulatory T cell present within tumor site systemic circulation individual . Conceivably , vaccination cancer patient tumor cell express high level CTAs combination regimens deplete inhibit T regulatory cell induce broad immunity antigen . In order examine issue , patient primary lung esophageal cancer , pleural mesothelioma , thoracic sarcoma , thymic neoplasms mediastinal germ cell tumor , well sarcomas , melanoma , germ cell tumor , epithelial malignancy metastatic lung , pleura mediastinum evidence disease ( NED ) minimal residual disease ( MRD ) follow standard multidisciplinary therapy vaccinate H1299 tumor cell lysates Iscomatrix adjuvant . Vaccines administer without metronomic oral cyclophosphamide ( 50 mg PO BID x 7d q 14d ) , celecoxib ( 400 mg PO BID ) . Serologic response variety recombinant CTAs well immunologic response autologous tumor epigenetically modify autologous EBVtransformed lymphocyte assess six month vaccination period . Primary Objectives : 1 . To assess frequency immunologic response CTAs patient thoracic malignancy follow vaccination H1299 cell lysate/Iscomatrix ( TM ) vaccines alone comparison patient thoracic malignancy follow vaccination H1299 cell lysate/Iscomatrix vaccine combination metronomic cyclophosphamide celecoxib . Secondary Objectives : 1 . To examine oral metronomic cyclophosphamide celecoxib therapy diminish number percentage T regulatory cell diminish activity cell patient thoracic malignancy risk recurrence . 2 . To examine H1299 cell lysate/Iscomatrix ( TM ) vaccination enhance immunologic response autologous tumor epigenetically modify autologous EBV-transformed lymphocyte ( B cell ) . Eligibility : - Patients histologically cytologically proven small cell non-small cell lung cancer ( SCLC ; NSCLC ) , esophageal cancer ( EsC ) , malignant pleural mesothelioma ( MPM ) , thymic mediastinal germ cell tumor , thoracic sarcoma , melanoma , sarcoma , epithelial malignancy metastatic lung , pleura mediastinum clinical evidence active disease ( NED ) , minimal residual disease ( MRD ) readily accessible non-invasive biopsy resection/radiation follow standard therapy complete within past 26 week . - Patients must 18 year old ECOG performance status 0 2 . - Patients must adequate bone marrow , kidney , liver , lung cardiac function . - Patients may systemic immunosuppressive medication time vaccination commence Design : - Following recovery surgery , chemotherapy , chemo/XRT , patient NED MRD vaccinate via IM injection H1299 cell lysates Iscomatrix ( TM ) adjuvant monthly 6 month . - Vaccines administer without metronomic oral cyclophosphamide celecoxib . - Systemic toxicity immunologic response therapy record . Pre post vaccination serologic cell mediate response standard panel CT antigens well autologous tumor cell ( available ) EBV-transformed lymphocyte assess vaccination . - Numbers/percentages function T regulatory cell peripheral blood assess , , vaccination . - Patients follow clinic routine staging scan disease recurrence . - The trial randomize 28 evaluable patient per arm either receive vaccine alone vaccine plus chemotherapy order 80 % power determine frequency immune response combination arm exceed vaccine alone arm , expect frequency immune response two arm 20 % 50 % , use one-sided 0.10 alpha level Fisher exact test . - Approximately 60 patient accrue trial .</brief_summary>
	<brief_title>Adjuvant Tumor Lysate Vaccine Iscomatrix With Without Metronomic Oral Cyclophosphamide Celecoxib Patients With Malignancies Involving Lungs , Esophagus , Pleura , Mediastinum</brief_title>
	<detailed_description>Background : During recent year , cancer-testis ( CT ) antigens ( CTA ) , particularly encode gene X chromosome ( CT-X gene ) , emerge attractive target cancer immunotherapy . Whereas malignancies diverse histology express variety CTAs , immune response protein appear uncommon cancer patient , possibly due low-level , heterogeneous antigen expression , well immunosuppressive regulatory T cell present within tumor site systemic circulation individual . Conceivably , vaccination cancer patient tumor cell express high level CTAs combination regimens deplete inhibit T regulatory cell induce broad immunity antigen . In order examine issue , patient primary lung esophageal cancer , pleural mesothelioma , thoracic sarcoma , thymic neoplasms mediastinal germ cell tumor , well sarcomas , melanoma , germ cell tumor , epithelial malignancy metastatic lung , pleura mediastinum evidence disease ( NED ) minimal residual disease ( MRD ) follow standard multidisciplinary therapy vaccinate H1299 tumor cell lysates Iscomatrix adjuvant . Vaccines administer without metronomic oral cyclophosphamide ( 50 mg PO BID x 7d q 14d ) , celecoxib ( 400 mg PO BID ) . Serologic response variety recombinant CTAs well immunologic response autologous tumor epigenetically modify autologous EBVtransformed lymphocyte assess receive 6 vaccine . Primary Objectives : 1 . To assess frequency immunologic response CTAs patient thoracic malignancy follow vaccination H1299 cell lysate/Iscomatrix ( TM ) vaccines alone comparison patient thoracic malignancy follow vaccination H1299 cell lysate/Iscomatrix vaccine combination metronomic cyclophosphamide celecoxib . Eligibility : -Patients histologically cytologically proven small cell non-small cell lung cancer ( SCLC ; NSCLC ) , esophageal cancer ( EsC ) , malignant pleural mesothelioma ( MPM ) , thymic mediastinal germ cell tumor , thoracic sarcoma , melanoma , sarcoma , epithelial malignancy metastatic lung , pleura mediastinum clinical evidence active disease ( NED ) , minimal residual disease ( MRD ) readily accessible non-invasive biopsy resection/radiation follow standard therapy complete within past 56 week . - Patients must 18 year old ECOG performance status 0 2 . - Patients must adequate bone marrow , kidney , liver , lung cardiac function . - Patients may systemic immunosuppressive medication time vaccination commence Design : - Following recovery surgery , chemotherapy , chemo/XRT , patient NED MRD vaccinate via deep subcutaneous ( SQ ) injection H1299 cell lysates Iscomatrix adjuvant monthly 6 vaccination give . - Vaccines administer without metronomic oral cyclophosphamide celecoxib . - Systemic toxicity immunologic response therapy record . Pre post vaccination serologic cell mediate response standard panel CT antigens well autologous tumor cell ( available ) EBV-transformed lymphocyte assess vaccination . - Numbers/percentages function T regulatory cell peripheral blood assess , , vaccination . - Patients follow clinic routine staging scan disease recurrence . - The trial randomize 28 evaluable patient per arm either receive vaccine alone vaccine plus chemotherapy order 80 % power determine frequency immune response combination arm exceed vaccine alone arm , expect frequency immune response two arm 20 % 50 % , use one-sided 0.10 alpha level Fisher exact test . - Approximately 60 patient accrue trial .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Thymoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>INCLUSION CRITERIA 2.1.1.1 Patients histologically cytologically proven lung esophageal cancer , thymic mediastinal germ cell tumor , malignant pleural mesothelioma , primary thoracic sarcoma , well patient sarcomas , melanoma , germ cell tumor , epithelial malignancy metastatic lung , mediastinum , pleura clinical evidence active disease ( NED ) minimal residual disease ( MRD ) readily accessible noninvasive biopsy resection/radiation follow standard therapy . 2.1.1.2 Diagnosis must confirm NCI Laboratory Pathology . 2.1.1.3 Patients must enrol within 56 week follow completion therapy . 2.1.1.4 Patients must complete standard therapy malignancy recover toxicity less equal grade 2 within 3 week prior enrollment . 2.1.1.5 Patients intracranial metastasis , treat surgery radiation therapy , may eligible study provide evidence active disease requirement anticonvulsant therapy steroid follow treatment . 2.1.1.6 Patients must ECOG performance status 0 2 2.1.1.7 Patients must 18 year age old due unknown effect immunologic response vaccine childhood adolescent development . 2.1.1.8 Patients must evidence adequate bone marrow reserve , hepatic renal function evidence follow laboratory parameter : Absolute neutrophil count great 1500/mm3 Platelet count great 100,000/mm3 Hemoglobin great 8g/dl ( patient may receive transfusion meet parameter ) PT within 2 second ULN Total bilirubin &lt; 1.5 x upper limit normal Serum creatinine less equal 1.6 mg/ml creatinine clearance must great 70 ml/min/1.73m2 . 2.1.1.9 Seronegative HIV antibody . Note : The experimental treatment evaluate protocol depend intact immune system . Patients HIV seropositive may decrease immune competence thus may less responsive experimental treatment . 2.1.1.10 Seronegative active hepatitis B , seronegative hepatitis C antibody . If hepatitis C antibody test positive , patient must test presence antigen RTPCR HCV RNA negative . 2.1.1.11 Patients must aware neoplastic nature illness , experimental nature therapy , alternative treatment , potential benefit , risk . 2.1.1.12 Patients must willing practice birth control four month follow treatment . 2.1.1.13 Patients must willing sign inform consent . EXCLUSION CRITERIA 2.1.2.1 Patients initially render NED MRD follow standard therapy exhibit disease progression prior initiation vaccination exclude study . 2.1.2.2 Patients require chronic systemic treatment steroid exclude . 2.1.2.3 Patients receive warfarin anticoagulation , transition agent enoxaparin dabigatran , anticoagulant hold 24 hour exclude . 2.1.2.4 Patients uncontrolled hypertension ( &gt; 160/95 ) , unstable coronary disease evidence uncontrolled arrhythmia , unstable angina , decompensated CHF ( &gt; NYHA Class II ) , myocardial infarction within 6 month study exclude . 2.1.2.5 Patients cardiac disease may exclude discretion PI follow consultation Cardiology consultant . 2.1.2.6 Patients follow pulmonary function abnormality exclude : FEV , &lt; 30 % predict ; DLCO &lt; 30 % predict ( postbronchodilator ) ; oxygen saturation le 92 % room air . 2.1.2.7 Pregnant and/or lactate woman exclude due unknown , potentially harmful effect immune response CTX antigens stem cell protein may express placenta , fetus , neonate . 2.1.2.8 Patients active infection , include HIV , exclude , due unknown effect vaccine lymphoid precursor . 2.1.2.9 Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation 3 month prior enrollment would limit compliance study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>September 26, 2016</verification_date>
	<keyword>Lung Cancer</keyword>
	<keyword>Cancer Vaccine</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Adjuvant Therapy</keyword>
	<keyword>Surgical Intervention</keyword>
</DOC>